Trypanosoma cruzi is the etiologic agent of Chagas disease, a neglected tropical disease
that affects millions of people mainly in Latin America. To establish a life-long infection, T …

Infection with the protozoan parasite Trypanosoma cruzi, the agent of Chagas disease, is
characterised by a variable clinical course–from symptomless cases to severe chronic …

Chagas disease is currently endemic to 21 Latin-American countries and has also become a
global concern because of globalization and mass migration of chronically infected …

Th17 cells are a subset of CD4+ T cells known to play a central role in the pathogenesis of
many autoimmune diseases, as well as in the defense against some extracellular bacteria …

We have demonstrated that modifying the tumor microenvironment through intratumoral
administration of adenoviral vectors (Ad) encoding the conditional cytotoxic molecule, ie …

Chagas disease is major public health problem, affecting nearly 10 million people,
characterized by cardiac alterations leading to congestive heart failure and death of 20-40 …

ABSTRACT A heterologous prime-boost strategy using plasmid DNA, followed by replication-
defective recombinant adenovirus 5, is being proposed as a powerful way to elicit CD4+ and …

Trypanosoma cruzi, the protozoan that causes Chagas disease, has a complex life cycle
involving insect and mammalian hosts and distinct developmental stages. During T. cruzi …

Chagas disease (CD) treatment and vaccine development are critical due to the significant
health burden caused by the disease, especially in Latin America. Current treatments …

Chagas' disease is caused by the protozoan Trypanosoma cruzi, described in the early 20th
century by the Brazilian physician Dr. Carlos Chagas. There was a great amount of research …